Discover How egnite's Real-World Data and AI Are Elevating Research
The Solution 
Improving Outcomes
This leading-edge solution delivers actionable insights through intuitive digital-health platforms, proprietary A.I. powered analytics and deep clinical expertise to help leading systems elevate the standard of patient care.
The Solution
Improving Outcomes
This leading-edge solution delivers actionable insights through intuitive digital-health platforms, proprietary A.I. powered analytics and deep clinical expertise to help leading systems elevate the standard of patient care.
egnite real-world data RESOURCES
Uncovering Cardiac Amyloidosis in EHR to Accelerate Rare Disease Therapy Access. View here.
From Echo to Innovation: Real-World Data Accelerating Algorithm Development. View here.
Unlock Early Market Signals with AI-Powered Cardiovascular Data. View here.
Uncovering Critical Breast Cancer Insights Hidden in EHR Notes. View here.
Additional Resources
Heart failure with a preserved ejection fraction (HFpEF) accounts for more than half of all heart failure cases and carries significant morbidity and mortality risk, especially after hospitalization1. Historically, management of the disease is largely focused on comorbidity management and lifestyle modifications, given that available therapies had not demonstrated sufficient impact on hospitalization burden or mortality. In recent years, however, the treatment paradigm for HFpEF has shifted, with a growing emphasis on SGLT2 inhibitors (SGLT2i). Originally developed to lower blood glucose levels in diabetic patients, several clinical trials have firmly established that SGLT2i is also beneficial for patients living with HFpEF2.
Heart failure with a preserved ejection fraction (HFpEF) accounts for more than half of all heart failure cases and carries significant morbidity and mortality risk, especially after hospitalization1. Historically, management of the disease is largely focused on comorbidity management and lifestyle modifications, given that available therapies had not demonstrated sufficient impact on hospitalization burden or mortality. In recent years, however, the treatment paradigm for HFpEF has shifted, with a growing emphasis on SGLT2 inhibitors (SGLT2i). Originally developed to lower blood glucose levels in diabetic patients, several clinical trials have firmly established that SGLT2i is also beneficial for patients living with HFpEF2.
ALISO VIEJO, Calif. – July 1, 2025 – egnite, Inc., a leading digital health company advancing cardiovascular innovation, today announced the launch of its new CardioCare Research Suite, a significant expansion of its flagship platform that enables hospitals to automatically identify patients eligible for clinical trials across participating health systems.